Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4021725 | 0.97 | MAPK1 (0.48) | MAPK1CYP3A4TSHRALDH1A1TDP1 | |
| SCHEMBL14303350 | 0.76 | SMN1; SMN2 (0.56) | MAPK1ALDH1A1KMT2APKMMAPT | |
| SCHEMBL13831900 | 0.75 | SMN1; SMN2 (0.60) | ALDH1A1KDM4EKMT2APKMMAPT | |
| SCHEMBL2321466 | 0.74 | LMNA (0.47) | ALDH1A1TDP1KDM4EKMT2APKM | |
| SCHEMBL2939873 | 0.74 | MAPK1 (0.50) | MAPK1CYP3A4TSHRALDH1A1TDP1 | |
| SCHEMBL25314314 | 0.74 | MAPT (0.51) | MAPK1CYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL9061256 | 0.74 | SMN1; SMN2 (0.38) | ALDH1A1KDM4EKMT2APKMMAPT | |
| SCHEMBL12112004 | 0.74 | MAPK1 (0.50) | MAPK1CYP3A4TSHRALDH1A1TDP1 | |
| SCHEMBL14303762 | 0.74 | CYP2A6 (0.42) | ALDH1A1KMT2APKMMAPTMEN1 | |
| SCHEMBL11308059 | 0.73 | ALDH1A1 (0.47) | MAPK1CYP3A4TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848713-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-31 | — | — | EP | claimed |
| US-20060116407-A1 | Amide derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-01 | — | — | US | claimed |
| WO-2006053778-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-26 | — | — | WO | claimed |
| EP-2858988-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9278981-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20150183801-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| EP-2858988-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | Novartis AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2119476-B1 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2013171640-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20040224966-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040102630-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-05-27 | — | — | US | disclosed |
| EP-1392662-A1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096888-A1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | WO | disclosed |
| EP-0154508-B1 | THIOPHENYLUREAS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-03-07 | — | — | EP | disclosed |
| US-4843100-A | Benzoylureas, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| US-4632938-A | INSECTICIDES, OVICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-12-30 | — | — | US | disclosed |
| EP-0154507-A2 | Benzoylureas, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-09-11 | — | — | EP | disclosed |
| US-4010179-A | ANTIMICROBIAL, ANTINEOPLASTIC | AMERICAN CYANAMID COMPANY (US) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116407-A1 | Amide derivatives | GLS, SDHA, GLS2 | MAPK1 3000/4885CYP3A4 50/4885TSHR 3006/4885 |
| US-20040102630-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | MAPK1 171/4885CYP3A4 1916/4885TSHR 3348/4885 |
| US-20040224966-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | MAPK1 174/4885CYP3A4 1946/4885TSHR 3409/4885 |
| US-20150183801-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | MAPK1 365/4885CYP3A4 2217/4885TSHR 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.